

SUPPLEMENTARY MATERIAL

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression $\geq 1\%$: A Retrospective Analysis of RATIONALE-305

Markus Moehler · Do-Youn Oh · Ken Kato · Tobias Arkenau · Josep Tabernero · Keun-Wook Lee · Sun Young Rha · Hidekazu Hirano · David Spigel · Kensei Yamaguchi · Lucjan Wyrwicz · Umut Diesel · Roberto Pazo Cid · Lorenzo Fornaro · Yaling Xu · Tao Sheng · Silu Yang · Alysha Kadva · Marcia Cruz-Correa · Rui-Hua Xu

M. Moehler

Department of Medicine, University Medical Center of Johannes Gutenberg University, Mainz, Germany

D.-Y. Oh

Department of Hemato-Oncology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

K. Kato

Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

T. Arkenau

Department of Oncology, Sarah Cannon Research, London, UK

J. Tabernero

Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain

K.-W. Lee

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

S. Y. Rha

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Republic of Korea

H. Hirano

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

D. Spigel

Department of Oncology, Tennessee Oncology, Nashville, TN, USA

K. Yamaguchi

Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, Tokyo, Japan

L. Wyrwicz

Department of Oncology and Radiotherapy, Maria Skłodowska-Curie National Cancer Research Institute, Warsaw, Poland

U. Disel

Department of Medical Oncology, Acibadem Adana Hospital, Adana, Turkey

R. A. Pazo-Cid

Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain

L. Fornaro

Department of Medical Oncology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

Y. Xu

Clinical Development, BeiGene (Shanghai) Co., Ltd., Shanghai, China

T. Sheng

Biostatistics, BeiGene USA, Inc., Emeryville, CA, USA

S. Yang

Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., Beijing, China

A. Kadva

Clinical Development, BeiGene USA, Inc., San Mateo, CA, USA

M. Cruz-Correa

School of Medicine, University of Puerto Rico, San Juan, Puerto Rico

Pan American Center for Oncology Trials, San Juan, Puerto Rico

R.-H. Xu

Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China

Corresponding author:

Rui-Hua Xu

Email: xurh@sysucc.org.cn

Contents

List of ethics committees by site number	4
--	---

Supplementary Tables	26
----------------------------	----

Supplementary Table S1. Key patient demographic and baseline characteristics in the CPS ≥ 1 and PD-L1 TAP score 1 to $< 5\%$ populations	26
---	----

Supplementary Table S2. Efficacy outcomes in the PD-L1 CPS ≥ 1 and PD-L1 TAP score 1% to $< 5\%$ populations at the final analysis	29
---	----

Supplementary Figures.....	31
----------------------------	----

Supplementary Fig. S1. Patient disposition in the PD-L1 TAP $\geq 1\%$ population	31
---	----

Supplementary Fig. S2. Kaplan–Meier curve of OS by baseline PD-L1 CPS of ≥ 1 at the final analysis (A) and 3-year follow-up (B)	32
--	----

Supplementary Fig. S3. Subgroup analysis of overall survival by baseline PD-L1 CPS score of ≥ 1 at the final analysis (efficacy-evaluable population)	33
--	----

Supplementary Fig. S4. Kaplan–Meier curve of OS by baseline PD-L1 TAP score 1% to $< 5\%$ at the final analysis	34
---	----

List of ethics committees by site number

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
001028	David Spigel (25May2021 to 03Jan2024 site closure) Johanna Bendell (05Mar2019 to 25May2021)	IntegReview Ethical Review Board (Advarra), 3815 S. Capital of Texas Highway, Austin, TX 78704	N/A - IRB does not issue an approval number.
001119	Efrat Dotan (13Oct2021 to 13Aug2024 to site closure) Rishi Jain (12Mar2021 to 13Oct2021) Crystal Denlinger (24Jul2019 to 12Mar2021)	Western Institutional Review Board, 1019 39th Avenue SE, Puyallup, WA 98374	20182456
001129	John Hays	Western Institutional Review Board, 1019 39th Avenue SE, Puyallup, WA 98374	20182456
001165	Arturo Loaiza-Bonilla (21Aug2021 to site closure) Eyal Meiri (07Jun2019 to 13May2021) Herbert Duvivier (13May2021 to 21Aug2021)	Copernicus Group IRB, 5000 CentreGreen Way, Cary, NC 27513 (part of WIRB)	20182456

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
001170	Terrance Cescon	Reading Hospital Institutional Review Board, 420 S. 5th Avenue, West Reading, PA 19611	N/A - IRB does not issue an approval number.
001175	Edward Kim (11Jan2021 to site closure) May Cho (17Jul2019 to 10Jan2021)	Institutional Review Board, University of California Davis, CTSC Building, Sacramento, CA 95817	N/A - IRB does not issue an approval number.
007013	Nadezhda Kovalenko	Local Ethics Committee at the State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary 400138, 78 Zemlyachki St., Volgograd, Russia	1/124 dd 04Oct2019
007020	Yana Chapko (08Dec2022 to site closure) Lyudmila Lebedeva (16Feb2022 to 07Dec2022) Marina Nechaeva (31May2019 to 15Feb2022)	Ministry of Healthcare of the Russian Federation Ethic Committee at Arkhangelsk Clinical Oncology Dispensary, 145 Bldg. 1 Obvodniy Kanal Ave., Arkhangelsk 163045, Russia	760 dd 04Feb2019
007026	Anastasia Zimina (06 Jun 2022 to site closure) Mikhail Vladimirovich Dvorkin (06Jun2019 to 06 Jun2022)	Ethics Committee at the Budgetary Healthcare Institution of the Omsk Region 'Clinical Oncology Dispensary,' 9/1 Zavertyaeva Str., Omsk 644013, Russia	12 dd 04Apr2019
007027	Evgeniy Gotovkin	Ethics Committee at RBIH "Ivanovo Regional Oncological Dispensary," 153040, 5 Lubimova St., Ivanovo, Russia	02/19 dd 27Feb2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
007028	Mikhail Kopp	Ethics Committee at the Private Institution of Higher Education Organization Reaviz Medical University/ 443030, 100 Chkalov St., Samara, Russia	1 dd 17Jan2019
007029	Fedor Vladimirovich Moiseenko	Local Ethics Committee of State Budgetary Healthcare Institution “Saint-Petersburg Clinical Research and Practical Center for specialized medical care (oncology),” lit A, 68A Leningradskaya str., pos. Pesochnyi, Saint Petersburg 197758, Russia	24 dd 25Mar2019
007030	Elena Poddubskaya	Ethics Committee at VitaMed LLC/ 121309, 10 Soslavinskaya St., Moscow, Russia	NA - IRB does not issue an approval number.
007032	Nikolay Kislov	The Independent Interdisciplinary Committee on Ethical Review of Clinical Studies / 125468 51, Leningradskiy prospect, Moscow, Russia	01 dd 18Jan2019
007034	Sergey Dvoretzkiy	Local Ethics Committee of Federal State Budgetary Educational Institution of Higher Education “First Saint-Petersburg state medical university named after academician I. P. Pavlov,” blud. 46, 6-8 Lva Tolstogo str, Saint Petersburg 197022, Russia	225 dd 25Dec2019
007039	Vadim Kozlov	Local Ethics Committee at State Budgetary Institution of Healthcare of the Novosibirsk Region “Novosibirsk Regional Clinical Oncological Dispensary,” 2 Plakhotnogo str., Novosibirsk 630108, Russia	2312/49 dd23Dec2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
007058	Sergey Orlov	Local Ethics Committee of Federal State Budgetary Educational Institution of Higher Education "First Saint-Petersburg state medical university named after academician I. P. Pavlov," blud. 46, 6-8 Lva Tolstogo str, Saint Petersburg 197022, Russia	225 dd 25Dec2019
033031	Denis Smith	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033038	Almotlak, Hamadi	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033044	Ghiringhelli, Francois	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033065	Evesque, Ludovic	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033070	Dahan, Laetitia	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	3690-I dd 23Jul2019
033074	Dahan, Laetitia	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin	3690-I dd 23Jul2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		Hospital], 89 rue d'Assas 75006 Paris France	
034003	Christophe Borg (01Oct2021 to site closure) Stefano Kim (27Feb2020 to 30Sept2021)	ILE DE FRANCE III - ETHICS COMMITTEE, Hôpital Tarnier-Cochin [Tarnier-Cochin Hospital], 89 rue d'Assas 75006 Paris France	01/2019 dd 09Jan2019
034006	Ana Ruiz Casado	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034017	Aitana Calvo Ferrandiz (22Jan2022 to site closure) Montserrat Blanco Codesido (30May 2019 to 22Jan2022)	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034018	Roberto Pazo Cid	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034021	Antonio Cubillo Gracian	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de	01/2019 dd 09Jan2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		Gobierno, Primera Planta, 28007 Madrid	
034026	Inmaculada Ales Diaz	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034027	Maria Luisa Limon Miron	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034030	Ana Belen Custodio Carretero	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034033	Tamara Sauri (15Nov2021 to site closure) Francis Esposito (27Apr2021 to 15Nov2021) Tamara Sauri (13May2019 to 27Apr2021)	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
034049	Tania Fleita Kanonnikoff	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034050	Borja Lopez De San Vicente Hernandez	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
034051	Javier Gallego Plazas	Comité de Ética de la Investigación con Medicamentos Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo 46, Pabellón de Gobierno, Primera Planta, 28007 Madrid	01/2019 dd 09Jan2019
039001	Mario Airoldi Paolo Pochettino	Comitato Etico Interaziendale AOU Città de la Salute e della Scienza di Torino Corso Bramante 88, Torino, Italy	CS2/1427 dd 17Oct2019
039008	Andrea Ardizzoni	COMITATO ETICO INDIPENDENTE DI AREA VASTA EMILIA CENTRO Via Albertoni 15, Bologna	158/2019/Farm/AOUB dd 20Mar2019
039018	Evaristo Maiello	Sezione del Comitato Etico IRCCS Istituto Tumori Giovanni Paolo II di Bari presso la Fondazione Casa Sollievo della Sofferenza di San Giovanni Rotondo (FG) Viale Cappuccini – 71013 San Giovanni Rotondo (FG)	07/2019 dd 28Jan2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
039032	Lorenzo Fornaro	COMITATO ETICO REGIONE TOSCANA - AREA VASTA NORD OVEST Via Roma 67, Pisa	14269_FORNARO dd 16May2019
039054	Silvia Stragliotto	Comitato Etico per la Sperimentazione Clinica dell'IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) ISTITUTO ONCOLOGICO VENETO VIA ANTENORE, 3, Padova	2019/05 dd 28Jan2019
039056	Rossana Berardi	Comitato Etico Regionale delle Marche Via Conca 71, Torrette di Ancona	2019 127 dd 11Apr2019
039057	Rossana Casaretti	Comitato Etico IRCCS Pascale, Napoli	93/18 dd 16Jan2019
039059	Mario Roselli	Comitato Etico IRCCS Pascale, Napoli	1/19 dd 23Jan2019
044010	Elisa Fontana (30Sep2022 to site closure) Hendrik-Tobias Arkenau (24Oct2019 to 29Sep2022)	East of England - Cambridge East Research Ethics Committee, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK	19/EE/0189 dd 23Jul2019
044061	Carys Angharad Morgan	East of England - Cambridge East Research Ethics Committee, The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK	19/EE/0189 dd 23Jul2019
048020	Jacek Jassem	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
048023	Lucjan Wyrwicz	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
048025	Justyna Borucka	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
048026	Małgorzata Ulanska	NIEZALEŻNA KOMISJA BIOETYCZNA DO SPRAW BADAŃ NAUKOWYCH, PRZY GDAŃSKIM UNIWERSYTECIE MEDYCZNYM, 80-210 Gdańsk, ul. M. Skłodowskiej-Curie 3a Poland	NKBBN/598/2018 dd 06Dec2018
081001	Taroh Satoh	Osaka University Hospital IRB, Yamadaoka 2-15, Suita-shi, Osaka-Fu, Japan, 565-0871	190040-B Approval date- 24Oct2019
081003	Hiroki Hara	Saitama Cancer Center IRB, Ina-machi Oaza Komuro 780, Kitaadachi-gun, Saitama-Ken, Japan, 362-0806	AA019-06 Approval date- 28May2019
081004	Keiko Minashi	Chiba Cancer Center IRB/Chuo-ku Nitona-cho 666-2, Chiba-shi, Chiba-Ken, Japan, 260-8717	201911 Approval date- 21Aug2019
081015	Hidekazu Hirano (Jul2020 to site closure)	National Cancer Center Hospital IRB, Tsukiji 5-1-1, Chuo-ku, Tokyo-To, Japan, 104-0045	T4712 Approval date- 03Sep2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
	Ken Kato (Aug2019 to Jul2020)		
081016	Takashi Oshima	Kanagawa Cancer Center IRB, Asahi-ku Nakao 2-3-2, Yokohama-shi, Kanagawa-Ken, Japan, 241-8515	治320 Approval date- 27Nov2019
081018	Kazuhiko Yamada	Center Hospital of the National Center for Global Health and Medicine IRB/Toyama 1-21-1, Shinjuku-ku, Tokyo-To, Japan, 162-8655	A-261-19a Approval date- 22Apr2019
081019	Yoshito Komatsu	Hokkaido University Hospital IRB, Kita-ku Kita 14jo Nishi 5, Sapporo-shi, Hokkaido, Japan, 060-8648	520 Approval date- 16Jul2019
081030	Taito Esaki	NHO Kyushu Cancer Center IRB, Minami-ku Notame 3-1-1, Fukuoka-shi, Fukuoka-Ken, Japan, 811-1395	520 Approval date- 20Nov2019
081032	Tomohiro Nishina	NHO Shikoku Cancer Center IRB, Minamiumemoto-machi Ko 160, Matsuyama-shi, Ehime-Ken, Japan, 791-0280	2019-14 Approval date- 05Sep2019
081033	Akihito Tsuji	Kagawa University Hospital IRB, Miki-cho Ikenobe 1750-1, Kita- gun, Kagawa-Ken, Japan, 761- 0793	N/A - IRB does not issue an approval number. Approval date- 23Apr2019
081048	Kensei Yamaguchi	Cancer Institute Hospital of JFCR IRB, Ariake 3-8-31, Koto-ku, Tokyo-To, Japan, 135-8550	2019-0008 Approval date- 23May2019

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
081049	Satoshi Otsu (Nov2021 to site closure) Shuichi Hironaka (May2019 to Nov2021)	Oita University Hospital IRB, Hasama-machi Idaigaoka 1-1, Yufu-shi, Oita-Ken, Japan, 879-5593	A19-001 Approval date-24May2019
081050	Tetsuya Hamaguchi	Saitama Medical University International Medical Center IRB, Yamane 1397-1, Hidaka-shi, Saitama-Ken, Japan, 350-1298	No.266 Approval date-26Aug2020
081056	Toru Masuzawa (Mar2021 to site closure) Atsushi Takeno (Sep2020 to Mar2021)	JOHAS Kansai Rosai Hospital IRB, Inabaso 3-1-69, Amagasaki-shi, Hyogo-Ken, Japan, 660-8511	20A047a Approval date-29Sep2020
081057	Hiroshi Tsukuda	Tokushukai Group IRB, Kojimachi 1-8-7, Chiyoda-ku, Tokyo-To, Japan, 102-0083	070-19-02 Approval date-03Sep2019
081058	Hiroya Takeuchi (Sep2019 to site closure) Yasuhide Yamada (Apr2019 to Sep2019)	Hamamatsu University School of Medicine, University Hospital IRB, Higashi-ku Handayama 1-20-1, Hamamatsu-shi, Shizuoka-Ken, Japan, 431-3192	694 Approval date-09Apr2019
081075	Yoshio Nagahisa	Kurashiki Central Hospital IRB, Miwa 1-1-1, Kurashiki-shi, Okayama-Ken, Japan, 710-8602	692 Approval date-16Sep2020
081076	Kunihiro Tsuji	Ishikawa Prefectural Central Hospital IRB, Kuratsukihigashi 2-1, Kanazawa-shi, Ishikawa-Ken, Japan, 920-8530	N/A - IRB does not issue an approval number. Approval date-14Apr2020

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
081077	Hisashi Hosaka	Gunma Prefectural Cancer Center IRB, Takahayashinishi-cho 617-1, Ota-shi, Gunma-Ken, Japan, 373-8550	R2-7 Approval date-25Sep2020
081078	Motohiro Hirao (Mar2021 to site closure) Kazuhiro Nishikawa (Aug2020 to Mar2021)	NHO Osaka National Hospital IRB, Chuo-ku Hoenzaka 2-1-14, Osaka-shi, Osaka-Fu, Japan, 540-0006	2020-0008 Approval date-24Sep2020
081079	Toshiyoshi Fujiwara	Okayama University Hospital IRB, Kita-ku Shikata-cho 2-5-1, Okayama-shi, Okayama-Ken, Japan, 700-8558	20200602 Approval date-28Aug2020
081080	Yu Oyama	Tesshokai Kameda General Hospital IRB, Higashi-cho 929, Kamogawa-shi, Chiba-Ken, Japan, 296-8602	N/A - IRB does not issue an approval number. Approval date-23Sep2020
081082	Yuji Ishibashi (Apr2021 to site closure) Kazuhiro Imamura (Jul2020 to Mar2021)	Tokyo Metropolitan Tama Medical Center IRB, Musashidai 2-8-29, Fuchu-shi, Tokyo-To, Japan, 183-8524	1052 Approval date-31Jul2020
082001	Sun Young Rha (29Jul2021 to site closure) HyunCheol Chung (21Aug2019 to 28Jul2021)	Severance Hospital Institutional Review Board 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea	4-2019-0438
082006	Young-lee Park	National Cancer Center Institutional Review Board, 323 Ilsan-ro (809 Madu-1-dong), Ilsandong-gu, Goyang-si Gyeonggi-do, Korea, 10408	NCC2019-0163

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
082013	Do-Youn Oh (30Jan2020 to site closure) Yung-Jue Bang (02Apr2019 to 30Jan2020)	Seoul National University Hospital Institutional Review Board, 101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea	H-1811-042-986
082020	Byoung Yong Shim	The Catholic University of Korea, St. Vincent Hospital Institutional Review Board, 93, Jungbu-daero, Paldal-gu, Suwon-si, Gyeonggi-do, 16247, Korea	VC19MDGT0119
082025	In Gyu Hwang	Chung-Ang University Hospital, 102, Heukseok-ro, Dongjak-gu, Seoul, 06973, Korea	1960-002-372
082026	Hyun Woo Lee	Ajou University Hospital Institutional Review Board 164, World cup-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16499, Korea	AJIRB-MED-CT3-19-192
082031	Keun Wook Lee	Seoul National University Bundang Hospital Institutional Review Board, 7th floor, 821-dong, 173, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707	B-1901/517-401
082032	Min-Hee Ryu (08 Nov 2023 to site closure) Yoon-Koo Kang (27 May 2019 to 08 Nov 2023)	Asan Medical Center Institutional Review Board, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul, 05505, Korea	2018-1415
082034	Ik Joo Chung	Chonnam National University Hwasun Hospital Institutional Review Board, Institutional Review Board, Chonnam National University Hwasun Hospital, 160, Ilsim-ri, Hwasun-	CNUHH-2018-170

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		eup, Hwasun-gun, Jeollanam-do, 519-809, Korea	
082036	Jong Gwang Kim	Kyungpook National University Chilgok Hospital Institutional Review Board, 807, Hoguk-ro, Buk-gu, Daegu, 41404, Korea	KNUCH 2019-05-021-001
086001	Lin Shen	Medical Ethics Committee of Beijing Cancer Hospital, No. 81 Fucheng Road, Haidian District, Beijing, China	2018YW39
086005	Dong Ma	Ethics Committee of Guangdong People`s Hospital, 23F, Haiyin Center, No 98 Donghua South Road, Yuexiu District, Guangzhou, Guangdong Province, China	2018-44-1
086006	Jufeng Wang	Ethics Committee of Henan Cancer Hospital, No.127 Dongming Road, Jinshui District, Zhengzhou, Henan Province, China.	2018106, 23Aug2028
086009	Chunmei Bai	Drug Clinical Trail Ethics Committee of Peking Union Medical College Hospital, No.41 Damucang Hutong, Xicheng District, Beijing, China	HS2018108
086012	Jiuwei Cui	Ethics Committee of The First Hospital of Jilin University, No.71 Xinmin Street, Changchun, Jilin, China	18Y107-001
086021	Yang Yang (26Mar2019 to site closure)	Ethics Committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Gulou	2018-145-01

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
	Baorui Li (31Jan2019 to 26Mar2019)	District, Nanjing, Jiangsu Province, China	
086022	Yuxian Bai	The Ethics Committee of Harbin Medical University Cancer Hospital, No.150 Haping Road, Nangang District, Harbin, Heilongjiang, China	2018-131, 17Oct2018
086024	Ruixing Zhang	Medical Ethics Committee of The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang City, Hebei Province, China	2018131, 4Jan2019
086027	Haijun Zhong	Ethics Committee of Zhejiang Cancer Hospital, 1 Banshan Dong Lu, Gongshu District, Hangzhou City, Zhejiang Province, China	IRB-[2018]438
086030	Rongsheng Zheng	Clinical Medical Research Ethics Committee of the First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Longzihu District, Bengbu City, Anhui Province	[2018]057
086031	Zhendong Chen	Ethics Committee of The Second Hospital of Anhui Medical University, No. 678 Furong Road, Jingkai District, Hefei, Anhui Province, China	YW2018-033(F1)
086032	Tianshu Liu	Ethics Committee of Zhongshan Hospital Fudan University, No.180 Fenglin Road, Xuhui District Shanghai, 200032, China	2018-113
086036	Zengqing Guo	Ethics Committee of Fujian Cancer Hospital, 420 Fumu	2018-038-01

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		Road, Jin 'an District, Fuzhou City, Fujian Province, China	
086037	Anwen Liu	Clinical Trial Ethic Committee of The Second Affiliated Hospital of Nanchang University, No.1 Minde Road, Nanchang City, Jiangxi Province, China 330006	[2018] No.14
086038	Hongming Pan	Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 9th Floor, Building 4, 3 Qingchun East Road, Shangcheng District, Hangzhou City, Zhejiang Province, China	20181016-4
086040	Tao Zhang	Clinical Trial Ethic Committee of Huazhong University of Science and Technology, No.1277, Jiefang Avenue, Jiangnan District, Wuhan, China	[2018] No.135
086042	Weiwei Shi	Ethics Committee of Chinese PLA General Hospital, No.28 Fuxing Road Beijing, 100853, China	C2018-035-01
086044	Lin Yang	Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences, NO.17 Panjiayuan Nanli, Chaoyang District, Beijing, China	18-122/1700
086047	Xiaochun Zhang	Medical Ethics Committee of the Affiliated Hospital of Qingdao University, No.16 Jiangsu Road., Qingdao, 266000, China	QYFYEC 2018-053-01
086048	Yi Ba	Ethics Committee of Tianjin Medical University Cancer Institute & Hospital, West Huan-	E2018155

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		Hu Rd, Ti Yuan Bei, Hexi District, Tianjin, 300060, China	
086049	Xianli Yin	Ethics Committee of Hunan Cancer Hospital, No.283 Tongzipo Road, Yuelu District, Changsha City, Hunan Province, China	2018 Drug No. [222]
086050	Liwen Ma	Ethics Committee Peking University Third Hospital, 6 / F, Great Wall Computer Building, Huayuan North Road, Haidian District, Beijing, China	(2018)DrugNo. 064-01)
086052	Ruihua Xu	Ethics Committee of Sun Yat-sen University Cancer Center, Room 315, Cuiyuan Building, 23 Xianlie South Road, Guangzhou City, Guangdong Province, China	A2018-015-01
086054	Xi Shi	Ethics Committee of The First Affiliated Hospital of Fujian Medical University, 11th floor, Outpatient Building, 20 Chazhong Road, Fuzhou City, Fujian Province, China	LY2018-016-01
086055	Sheng Hu	Ethics Committee of Hubei Cancer Hospital, 116 Zhuodaoquan South Road, Hongshan District, Wuhan City, Hubei Province, China	[2018] No.26
086060	Ping Gan	Ethics Committee of Yunnan Cancer Hospital, No. 519 Kunzhou Road, Xishan District, Kunming, Yunnan Province, China	YW201827-27Aug2018

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
086072	Yunpeng Liu	Ethics Committee of The First Hospital of China Medical University, No.155 of Nanjing North Street, Heping District, and No.210 of Baita First Street, Hunnan District Shenyang City, Liaoning Province, China	2018YL035
086074	Jianhua Shi	Ethics Committee of Linyi Cancer Hospital, Intersection of Zhicheng Road and Zhongsheng Street, Hedong District, Linyi, Shandong Province, China, 276034	XY1825
086075	Jingdong Zhang	Ethics Committee of Liaoning Cancer Hospital, No.44 of Xiaoheyuan Road, Dadong District, Shenyang City, Liaoning Province, China	20180754
086077	Hong Shen	Human Research Ethics Committee, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou City, Zhejiang Province, China	(2018) Drug No. (534)
086078	Shan Zeng	Ethics Committee of Xiangya Hospital Central South University, No.87 Xiangya Road, Kaifu District, Changsha City, Hunan Province, China	No. 201812161
086080	Jun Zhang	Ethics Committee of Drug Clinical Trials of Ruijin Hospital Shanghai Jiaotong University School of Medicine, No.197 Ruijin Second Road, Huangpu District, Shanghai, China	(2018) No. (81) -3
086083	Lei Yang	Ethics Committee of Nantong Tumor Hospital, No.48 Qingnian	[2018-009], 7Sep2018

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
		West Road, Chongchuan District, Nantong, 226000, China	
086086	Yulong Zheng	Clinical Research Ethics Committee, The First Affiliated Hospital of Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China	(2018) No. (268)
086089	Lin Wang	Ethics Committee of Hainan General Hospital, No.19 Xiuhua Road, Xiuying District, Haikou, Hainan, China, 570311.	[2018] No.72
086102	Changzheng Li	Medical Ethics Committee of Shandong First Medical University Affiliated Cancer Hospital, No.440 Jiyan Road Jinan, Shandong, China	SDZLEC2018-052-01
086103	Yanru Qin	Scientific Research and Clinical Trial Ethics Committee of The First Affiliated Hospital of Zhengzhou University, NO.1 East Jianshe Road, Erqi District, Zhengzhou City, Henan Province, China	Drug-2018-119
086113	Bangwei Cao	Bioethics Committee, Beijing Friendship Hospital, Capital Medical University, 95 Yong 'an Road, Xicheng District, Beijing, 602, Unit 2, Physical Examination Center, Beijing Friendship Hospital, 92 Yong 'an Road, Xicheng District, Beijing, China	2018-P1-Drug 021-01
086115	Yifu He	Ethics Committee of Anhui Provincial Cancer Hospital, No.107 Huanhudong Road, Hefei, Anhui Province, China	2018-EC comments-19-01

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
086124	Dong Wang	Ethics Committee of Army Specialty Medical Center of the Chinese People's Liberation Army, No.10 Changjiang Road, Daping, Yuzhong District, Chongqing, China	Drug (2018) No. 03
086127	Diansheng Zhong	Ethics Committee of Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin, China	IRB2018-055-01
086144	Mafei Kang	Ethics Committee of Affiliated Hospital of Guilin Medical University, No. 15 Lequn Road, Xiufeng District, Guilin, Guangxi Province, China	No. (F2019009)
086150	Zhendong Zheng	Ethics Committee of Northern Theater Command of Chinese People's Liberation Army, No.83 Wenhua Road, Shenhe District, Shenyang City, Liaoning Province, China	No. (2018) 15
086151	Leizhen Zheng	Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No.1665, Kongjiang Road, Yangpu District, Shanghai, China	XHEC-A-2018-005-1
086152	Ruilian Xu	Ethics Committee of Shenzhen People's Hospital, No. 1017 Dongmen North Road, Luohu District, Shenzhen, Guangdong Province, China	No. (2018) 72
086153	Qi Li	Medical Ethics Committee of Shanghai General Hospital, 85 Wujin Road, Hongkou District, Shanghai, China	No. (2018) 71

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
086154	Wei Wang	Ethics Committee of The First People's Hospital of Foshan, No.81 North Lingnan Avenue, Foshan, Guangdong, China, 528000.	Drug No. (2018) 12
086155	Xiuling Li	Ethics Committee of Henan Provincial People's Hospital, No.7 Weiwu Road, Jinshui District, Zhengzhou, Henan Province, 450003, China	2018-028-02
086162	Guangyu An	Ethics Committee of Beijing Chao Yang Hospital, No.8 Gongti Nan Road, Chaoyang District, Beijing, China	2018-10-10-2 No.2018-Drug-23
086169	Dong Yan	Ethics Committee Beijing Luhe Hospital, Capital Medical University, Room 322, Building 4, Adult Education Center, 358 Yudaihe East Street, Tongzhou District, Beijing, China	2018-LHYW-061-03
086206	Qinghong Guo	Ethics Committee of The First Hospital Of Lanzhou University, No.1 Donggang West Road Lanzhou, 730000, China	2019 No.(20)号, 12Jun2019
090001	Ali Murat Tatli(11Feb2022 to site closure) Hasan Senol Coskun (20Aug2019 to 11Feb2022)	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
090002	Umut Disel	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018

Site No.	Principal Investigator Name	Name/Address of Ethics Committee	Approval number
090003	Hakan Harputluoglu	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
090004	Ozturk Ates(04Nov2022 to site closure) Berna Oksuzoglu (08Nov2019 to 04Nov2022)	Malatya Clinical Trials Ethics Committee, Inonu Universitesi Merkez Kampusu, 44280, Malatya, Turkey	2018/155 dd 14Nov2018
787001	Marcia Cruz-Correa	Copernicus Group IRB, 5000 CentreGreen Way, Cary, NC 27513 (part of WIRB)	20182456
886001	Jawyuan Wang	Institutional Review Board Kaohsiung Medical University Chung-Ho Memorial Hospital, No. 100, Tzyou 1st Road, Kaohsiung 807, Taiwan	NA - IRB does not issue an approval number.
886042	Chiajui Yen	Institutional Review Board National Cheng Kung University Hospital, No 138, Sheng-Li Road, Tainan 704, Taiwan	NA - IRB does not issue an approval number.
886045	Yi-Ping Hung (3Nov2022 to site closure) Yee Chao (8May2019-3Nov2022)	Institutional Review Board Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 11217, Taiwan	No.1084900050

Supplementary Tables

Supplementary Table S1. Key patient demographic and baseline characteristics in the CPS ≥ 1 and PD-L1 TAP score 1 to $< 5\%$ populations

Demographic/characteristics	PD-L1 CPS ≥ 1		PD-L1 TAP score 1% to $< 5\%$	
	Tislelizumab plus ICC (<i>n</i> = 420)	Placebo plus ICC (<i>n</i> = 434)	Tislelizumab plus ICC (<i>n</i> = 158)	Placebo plus ICC (<i>n</i> = 181)
Age, <i>n</i> (%)				
Median (range)	60.5 (23.0–86.0)	61.0 (25.0–86.0)	60.0 (27.0–86.0)	59.0 (25.0–86.0)
≥ 65 years, <i>n</i> (%)	143 (34.0)	162 (37.3)	50 (31.6)	53 (29.3)
Sex, <i>n</i> (%)				
Female	127 (30.2)	132 (30.4)	46 (29.1)	66 (36.5)
Male	293 (69.8)	302 (69.6)	112 (70.9)	115 (63.5)
Race/ethnicity, <i>n</i> (%)				
Asian	319 (76.0)	331 (76.3)	123 (77.8)	137 (75.7)
Chinese	211 (50.2)	223 (51.4)	84 (53.2)	97 (53.6)
Korean	61 (14.5)	59 (13.6)	28 (17.7)	25 (13.8)
Japanese	47 (11.2)	49 (11.3)	11 (7.0)	15 (8.3)
White	93 (22.1)	91 (21.0)	34 (21.5)	38 (21.0)
Other ^a	8 (1.9)	12 (2.7)	1 (0.6)	6 (3.3)
Region, <i>n</i> (%)				
East Asia	319 (76.0)	331 (76.3)	123 (77.8)	137 (75.7)
China (including Taiwan)	211 (50.2)	222 (51.2)	84 (53.2)	97 (53.6)
South Korea	61 (14.5)	60 (13.8)	11 (7.0)	15 (8.3)
Japan	47 (11.2)	49 (11.3)	28 (17.7)	25 (13.8)
Rest of the world	101 (24.0)	103 (23.7)	35 (22.2)	44 (24.3)
ECOG performance status, <i>n</i> (%)				
0	144 (34.3)	141 (32.5)	51 (32.3)	59 (32.6)
1	276 (65.7)	293 (67.5)	107 (67.7)	122 (67.4)

Time from initial diagnosis to study entry, median (range), months ^b	1.5 (0.3–442.1)	1.6 (0.2–190.2)	2.2 (0.5–175.3)	1.8 (0.2–138.1)
Disease state at study entry, <i>n</i> (%)				
Locally advanced	6 (1.4)	4 (0.9) ^c	2 (1.3)	0 (0.0)
Metastatic disease	414 (98.6)	430 (99.1)	156 (98.7)	181 (100.0)
Number of metastatic sites at study entry, <i>n</i> (%) ^d				
0–2	282 (67.1)	290 (66.8)	107 (67.7)	118 (65.2)
≥ 3	138 (32.9)	143 (32.9)	51 (32.3)	62 (34.3)
Liver metastases, <i>n</i> (%)	166 (39.5)	169 (38.9)	49 (31.0)	63 (34.8)
Peritoneal metastases, <i>n</i> (%)	185 (44.0)	186 (42.9)	80 (50.6)	89 (49.2)
Primary tumor location, <i>n</i> (%) ^e				
Stomach	338 (80.5)	349 (80.4)	124 (78.5)	148 (81.8)
Gastroesophageal junction	82 (19.5)	85 (19.6)	34 (21.5)	33 (18.2)
Histologic type (Lauren classification), <i>n</i> (%)				
Diffuse type	86 (20.5)	92 (21.2)	32 (20.3)	37 (20.4)
Intestinal type	70 (16.7)	80 (18.4)	26 (16.5)	31 (17.1)
Mixed type	25 (6.0)	32 (7.4)	10 (6.3)	8 (4.4)
Unknown	239 (56.9)	230 (53.0)	90 (57.0)	105 (58.0)
MSI or MMR status, <i>n</i> (%)				
MSI-H/dMMR	15 (3.6)	20 (4.6)	5 (3.2)	6 (3.3)
MSI-L/MSS/pMMR	376 (89.5)	385 (88.7)	140 (88.6)	163 (90.1)
Unknown	29 (6.9)	29 (6.7)	13 (8.2)	12 (6.6)
Previous adjuvant/neoadjuvant treatment, <i>n</i> (%)	87 (20.7)	83 (19.1)		
Adjuvant	73 (17.4)	77 (17.7)	47 (29.7)	42 (23.2)
Neoadjuvant	25 (6.0)	12 (2.8)	11 (7.0)	8 (4.4)
Previous gastrectomy/esophagectomy, <i>n</i> (%)	109 (26.0)	120 (27.6)	61 (38.6)	65 (35.9)
ICC, <i>n</i> (%)				
Oxaliplatin and capecitabine	392 (93.3)	407 (93.8)	148 (93.7)	170 (93.9)
Cisplatin and 5-fluorouracil	28 (6.7)	27 (6.2)	10 (6.3)	11 (6.1)
PD-L1 CPS expression, <i>n</i> (%)				
≥ 5	254 (60.5)	269 (62.0)	–	–
≥ 10	151 (36.0)	138 (31.8)	–	–

CPS combined positive score, *dMMR* mismatch repair deficient, *ECOG* Eastern Cooperative Oncology Group, *ICC* investigator-chosen chemotherapy, *MSI-H/L* microsatellite instability-high/low, *MSS* microsatellite stable, *PD-L1* programmed death-ligand 1, *pMMR* mismatch repair proficient

^aIncludes not reported, unknown, and other

^bStudy entry date refers to randomization date

^cOne patient in the placebo plus chemotherapy arm had locally recurrent disease

^dOne patient in the placebo plus chemotherapy arm had the metastatic site removed by surgery before study entry

^eThe diagnosis of one patient the placebo plus chemotherapy arm was updated from gastric adenocarcinoma to pancreatic cancer after randomization

Supplementary Table S2. Efficacy outcomes in the PD-L1 CPS ≥ 1 and PD-L1 TAP score 1% to < 5% populations at the final analysis

	PD-L1 CPS ≥ 1		PD-L1 TAP score 1% to < 5%	
	Tislelizumab plus ICC (n = 420)	Placebo plus ICC (n = 434)	Tislelizumab plus ICC (n = 158)	Placebo plus ICC (n = 181)
PFS				
Events, n (%)	303 (72.1)	348 (80.2)	127 (80.4)	148 (81.8)
Median (95% CI), months	7.0 (5.7–7.7)	6.4 (5.6–6.9)	5.6 (5.1–6.9)	6.2 (5.5–7.1)
HR ^a	0.77 (0.66–0.90)		0.98 (0.77–1.24)	
PFS rate at 12 months, % (95% CI)	31.5 (26.7–36.3)	21.5 (17.4–25.8)	23.8 (17.1–31.2)	22.6 (16.4–29.4)
ORR				
n (%)	204 (48.6)	183 (42.2)	65 (41.1)	70 (38.7)
95% CI ^b	43.7–53.5	37.5–47.0	33.4–49.2	31.5–46.2
Odds ratio for ORR (95% CI) ^c	1.30 (0.99–1.71)		1.10 (0.71–1.70)	
DoR ^d				
Median (95% CI), months	8.6 (7.8–10.4)	7.2 (5.8–8.5)	6.8 (4.8–9.5)	7.2 (5.6–10.5)
DCR				
n (%)	376 (89.5)	363 (83.6)	145 (91.8)	147 (81.2)
95% CI ^b	86.2–92.3	79.8–87.0	86.3–95.5	74.8–86.6

The data cutoff was February 28, 2023. ORR is defined as the proportion of patients with a confirmed PR or CR per RECIST v1.1. DCR is defined as the proportion of patients with a PR, CR, or SD (i.e., patients with non-CR or non-progressive disease)

CPS combined positive score, CI confidence interval, CR complete response, DCR disease control rate, DoR duration of response, HR hazard ratio, ICC investigator-chosen chemotherapy, ORR objective response rate, PD-L1 programmed death-ligand 1, PFS progression-free survival, PR partial response, SD stable disease

^aStratified by regions (East Asia vs. rest of the world) and presence of peritoneal metastasis


^bExact Clopper-Pearson 2-sided CI

^cORR, ORR differences, and odds ratios between arms were calculated using the Cochran-Mantel-Haenszel method, stratified by regions (East Asia vs. rest of the world) and presence of peritoneal metastasis

^dDoR analysis included patients with confirmed CR or PR. Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley

Supplementary Figures

Supplementary Fig. S1. Patient disposition in the PD-L1 TAP $\geq 1\%$ population




The data cutoff was February 28, 2023.


COVID-19 Coronavirus disease 2019, *ICC* investigator-chosen chemotherapy, *ITT* intent-to-treat, *PD-L1* programmed death-ligand 1, *TAP* Tumor Area Positivity.

Supplementary Fig. S2. Kaplan–Meier curve of OS by baseline PD-L1 CPS of ≥ 1 at the final analysis (A) and 3-year follow-up (B)

A




B



A The data cutoff was February 28, 2023. The red circles and gray triangles represent censored patients. B The data cutoff was February 28, 2024. The '+' symbol represents censored patients. Primary OS analysis: stratified by regions (East Asia vs. rest of the world) and presence of peritoneal metastasis. Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.


OS rates were estimated by Kaplan-Meier method with 95% CIs estimated using Greenwood's formula. CI confidence interval, CPS combined positive score, ICC investigator-chosen chemotherapy, (m)OS (median) overall survival, PD-L1 programmed death-ligand 1.

Supplementary Fig. S3. Subgroup analysis of overall survival by baseline PD-L1 CPS score of ≥ 1 at the final analysis (efficacy-evaluable population)



The data cutoff was February 28, 2023. Medians were estimated by Kaplan–Meier method, with 95% CIs estimated using the method of Brookmeyer and Crowley using log-log transformation. The HR and its 95% CI were estimated from an unstratified Cox regression model including treatment as a covariate. The race subcategory 'Other' includes not reported, unknown, and other. The range of the x-axis for HR is (0, 3), some extreme 95% CI values greater than 3 are not shown in the plot. *CI* confidence interval, *CPS* combined positive score, *dMMR* mismatch repair deficient, *HR* hazard ratio, *ICC* investigator-chosen chemotherapy, *MSI-H/L* microsatellite instability high/low, *MSS* microsatellite stable, *pMMR* mismatch repair proficient

Supplementary Fig. S4. Kaplan–Meier curve of OS by baseline PD-L1 TAP score 1% to < 5% at the final analysis



The data cutoff was February 28, 2023. The red circles and gray triangles represent censored patients. Primary OS analysis: stratified by regions (East Asia vs. rest of the world) and presence of peritoneal metastasis. Medians were estimated by Kaplan-Meier method, with 95% CIs estimated using the method of Brookmeyer and Crowley.

CI confidence interval, CPS combined positive score, ICC investigator-chosen chemotherapy, (m)OS (median) overall survival, PD-L1 programmed death-ligand 1, TAP Tumor Area Positivity.